NEW DRUG: Ebglyss for atopic dermatitis

Ebglyss for atopic dermatitislebrikizumab solution for SC injection; 250 mg/2 mL single-use prefilled pen or prefilled syringe with needle shield, Eli Lilly.INDICATIONS Treatment of moderate-to-severe atopic dermatitis in adults and adolescents (≥ 12 years of age with a body weight of ≥ 40 kg), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Can be used with or without topical corticosteroids or topical calcineurin inhibitors.ACTION Interleukin-13 (IL-13) is found in higher amounts in people with atopic dermatitis. Lebrikizumab is a monoclonal antibody that inhibits (IL-13) signaling, which blocks the downstream effects of IL-13. This results in a reduction in inflammation, an improvement in skin condition, and reductions in itch, redness and scaling.DOSAGE Initial doses of 500 mg (two 250 mg injections) SC at Week 0 and Week 2, followed by 250 mg (one injection) SC every two weeks until Week 16. Once clinical response is achieved, the recommended maintenance dose is 250 mg SC every four weeks starting at Week 16.ADMINISTRATION Administer SC into the abdomen, thigh or back of the upper arm. Rotate injection sites. Patients and/or caregivers can be trained on the subcutaneous injection technique.ADVERSE EFFECTS MOST COMMON: Conjunctivitis, injection site reactions, allergic conjunctivitis, dry eye, herpes zoster. MOST SERIOUS: Hypersensitivity reactions have been reported. Potential for immunogenicity.DRUG INTERACTIONS No formal drug interaction studies have been conducted. No pharmacokinetic drug interactions are expected. Give live (attenuated) vaccines before starting lebrikizumab treatment.STORAGE Store refrigerated at 2°C–8°C in the original carton to protect from light. If necessary, may be kept at room temperature (up to 30°C) for up to seven days in the original carton.

NEW DRUG: Ebglyss for atopic dermatitis

Register for free access or login.

Related Topics